protocol

[키워드] 24 hour addition Administered adverse event all subject allocation sequence Analysis antiviral activity Antiviral effect Arm arrhythmia Asymptomatic bradycardia can be used carried Cell Chronic kidney disease clinical Cluster Clusters Comorbidity Compliance conducted congestive heart failure Contact contraindication Coronaviruses covariates COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient COVID-19 patients COVID-19 symptom Data monitoring committee database deficiency defined Department diabete diagnostic dialysis disease dissemination diuretics dose drug Drug-drug interactions during treatment early treatment Efficacy element eligible endosomal pH ENhance enrolled Epidemic Epidemiology equation EudraCT evaluate Evidence expected Factor female Final G6PD Generalized generate Glucose-6-phosphate glycosylation group Healthcare professional Hydroxychloroquine hydroxychloroquine/chloroquine identify in vitro in vivo inclusion criteria independent index index case index cases Infection interim analysis involved IRCCS ischemic heart disease Italian region Italy Loading dose male malignancy medication mental illness mild symptoms neurological number objective observation open label oropharyngeal swab outcome parallel group participant Patient patients with COVID-19 Paucisymptomatic performed positive PCR test Prevent prevention prevention of COVID-19 Prophylaxis proportion Proteins protocol protocol amendment Public QT prolongation randomization Randomized Randomized controlled clinical trial Randomized controlled trial reached receive recorded recruited reduced reduction in Registered reported required risk Sample size SARS-CoV-2 shown Standard status stratified Studio Study protocol subject subjects Support Swab Symptom symptomatic syndrome Tablet therapeutic approaches therapy Toxicity treat treated Treatment Trial trial protocol ventricular viral surface virus virus infection website with COVID-19
[DOI] 10.1186/s13063-020-04527-4 PMC 바로가기 [Article Type] Study Protocol